Peritoneal Cancer - Pipeline Review, H2 2017

  • ID: 4410072
  • Report
  • 876 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • BeiGene Ltd
  • EpiThany Inc
  • Immunovaccine Inc
  • MolMed SpA
  • Oxford BioMedica Plc
  • MORE
Peritoneal Cancer - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Peritoneal Cancer - Pipeline Review, H2 2017, provides an overview of the Peritoneal Cancer (Oncology) pipeline landscape.

Peritoneal cancer is a rare cancer that develops in the peritoneum, a thin, delicate sheet that lines the inside wall of the abdomen and covers the uterus and extends over the bladder and rectum. Peritoneal cancer usually manifests with abdominal distention and diffuse nonspecific abdominal pain secondary to ascites. Peritoneal cancer symptoms may include shortness of breath, rectal bleeding, loss of appetite, frequent urination, constipation, nausea or diarrhea and feeling of fullness, even after a light meal. Treatment includes options such as chemotherapy, surgery, biological therapy and radiation therapy.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Peritoneal Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Peritoneal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peritoneal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peritoneal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 12, 63, 37, 17, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 6 and 2 molecules, respectively.

Peritoneal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from a proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peritoneal Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Peritoneal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peritoneal Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peritoneal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peritoneal Cancer (Oncology)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peritoneal Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peritoneal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3-V Biosciences Inc
  • BeiGene Ltd
  • EpiThany Inc
  • Immunovaccine Inc
  • MolMed SpA
  • Oxford BioMedica Plc
  • MORE
Introduction

Peritoneal Cancer - Overview

Peritoneal Cancer - Therapeutics Development

Peritoneal Cancer - Therapeutics Assessment

Peritoneal Cancer - Companies Involved in Therapeutics Development

Peritoneal Cancer - Drug Profiles

Peritoneal Cancer - Dormant Projects

Peritoneal Cancer - Discontinued Products

Peritoneal Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Peritoneal Cancer, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Companies, H2 2017 (Contd..1), H2

Number of Products under Development by Companies, H2 2017 (Contd..2), H2

Number of Products under Development by Companies, H2 2017 (Contd..3), H2

Number of Products under Development by Companies, H2 2017 (Contd..4), H2

Number of Products under Development by Companies, H2 2017 (Contd..5), H2

Number of Products under Development by Universities/Institutes, H2

Products under Development by Companies, H2

Products under Development by Companies, H2 2017 (Contd..1), H2

Products under Development by Companies, H2 2017 (Contd..2), H2

Products under Development by Companies, H2 2017 (Contd..3), H2

Products under Development by Companies, H2 2017 (Contd..4), H2

Products under Development by Companies, H2 2017 (Contd..5), H2

Products under Development by Companies, H2 2017 (Contd..6), H2

Products under Development by Companies, H2 2017 (Contd..7), H2

Products under Development by Universities/Institutes, H2

Number of Products by Stage and Target, H2

Number of Products by Stage and Target, H2 2017 (Contd..1), H2

Number of Products by Stage and Target, H2 2017 (Contd..2), H2

Number of Products by Stage and Target, H2 2017 (Contd..3), H2

Number of Products by Stage and Target, H2 2017 (Contd..4), H2

Number of Products by Stage and Target, H2 2017 (Contd..5), H2

Number of Products by Stage and Mechanism of Action, H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..2), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..3), H2

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..4), H2

Number of Products by Stage and Route of Administration, H2

Number of Products by Stage and Molecule Type, H2

Peritoneal Cancer - Pipeline by 3-V Biosciences Inc, H2

Peritoneal Cancer - Pipeline by AbbVie Inc, H2

Peritoneal Cancer - Pipeline by Adaptimmune Therapeutics Plc, H2

Peritoneal Cancer - Pipeline by Aduro BioTech Inc, H2

Peritoneal Cancer - Pipeline by Advenchen Laboratories LLC, H2

Peritoneal Cancer - Pipeline by Altor BioScience Corp, H2

Peritoneal Cancer - Pipeline by Amgen Inc, H2

Peritoneal Cancer - Pipeline by Arrien Pharmaceuticals LLC, H2

Peritoneal Cancer - Pipeline by Astellas Pharma Inc, H2

Peritoneal Cancer - Pipeline by Astex Pharmaceuticals Inc, H2

Peritoneal Cancer - Pipeline by AstraZeneca Plc, H2

Peritoneal Cancer - Pipeline by Atara Biotherapeutics Inc, H2

Peritoneal Cancer - Pipeline by AVEO Pharmaceuticals Inc, H2

Peritoneal Cancer - Pipeline by Bayer AG, H2

Peritoneal Cancer - Pipeline by BeiGene Ltd, H2

Peritoneal Cancer - Pipeline by Boehringer Ingelheim GmbH, H2

Peritoneal Cancer - Pipeline by Boston Biomedical Inc, H2

Peritoneal Cancer - Pipeline by Bristol-Myers Squibb Co, H2

Peritoneal Cancer - Pipeline by Celgene Corp, H2

Peritoneal Cancer - Pipeline by Celldex Therapeutics Inc, H2

Peritoneal Cancer - Pipeline by Celsion Corp, H2

Peritoneal Cancer - Pipeline by CerRx Inc, H2

Peritoneal Cancer - Pipeline by Chipscreen Biosciences Ltd, H2

Peritoneal Cancer - Pipeline by Clovis Oncology Inc, H2

Peritoneal Cancer - Pipeline by Critical Outcome Technologies Inc, H2

Peritoneal Cancer - Pipeline by Dr. Reddy's Laboratories Ltd, H2

Peritoneal Cancer - Pipeline by Eisai Co Ltd, H2

Peritoneal Cancer - Pipeline by Eli Lilly and Co, H2

Peritoneal Cancer - Pipeline by EpiThany Inc, H2

Peritoneal Cancer - Pipeline by Exelixis Inc, H2

Peritoneal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H2

Peritoneal Cancer - Pipeline by Galena Biopharma Inc, H2

Peritoneal Cancer - Pipeline by Gene Techno Science Co Ltd, H2

Peritoneal Cancer - Pipeline by Genelux Corp, H2

Peritoneal Cancer - Pipeline by Genentech Inc, H2

Peritoneal Cancer - Pipeline by Genor BioPharma Co Ltd, H2

Peritoneal Cancer - Pipeline by Glycotope GmbH, H2

Peritoneal Cancer - Pipeline by Gradalis Inc, H2

Peritoneal Cancer - Pipeline by Hemispherx Biopharma Inc, H2

Peritoneal Cancer - Pipeline by ImmunoGen Inc, H2

Peritoneal Cancer - Pipeline by Immunovaccine Inc, H2

Peritoneal Cancer - Pipeline by Innate Immunotherapeutics Ltd, H2

Peritoneal Cancer - Pipeline by Innate Pharma SA, H2

Peritoneal Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2

Peritoneal Cancer - Pipeline by Johnson & Johnson, H2

Peritoneal Cancer - Pipeline by Juno Therapeutics Inc, H2

Peritoneal Cancer - Pipeline by Kyowa Hakko Kirin Co Ltd, H2

Peritoneal Cancer - Pipeline by Lidds AB, H2

Peritoneal Cancer - Pipeline by Mabion SA, H2

Peritoneal Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H2

Peritoneal Cancer - Pipeline by Madrigal Pharmaceuticals Inc., H2

Peritoneal Cancer - Pipeline by MedImmune LLC, H2

Peritoneal Cancer - Pipeline by Medivir AB, H2

Peritoneal Cancer - Pipeline by Merck & Co Inc, H2

Peritoneal Cancer - Pipeline by Merck KGaA, H2

Peritoneal Cancer - Pipeline by Millennium Pharmaceuticals Inc, H2

Peritoneal Cancer - Pipeline by MolMed SpA, H2

Peritoneal Cancer - Pipeline by Mycenax Biotech Inc, H2

Peritoneal Cancer - Pipeline by NewLink Genetics Corp, H2

Peritoneal Cancer - Pipeline by Novartis AG, H2

Peritoneal Cancer - Pipeline by Novogen Ltd, H2

Peritoneal Cancer - Pipeline by Oasmia Pharmaceutical AB, H2

Peritoneal Cancer - Pipeline by OBI Pharma Inc, H2

Peritoneal Cancer - Pipeline by Oncobiologics Inc, H2

Peritoneal Cancer - Pipeline by Oncolix Inc, H2

Peritoneal Cancer - Pipeline by Oncolytics Biotech Inc, H2

Peritoneal Cancer - Pipeline by OncoMed Pharmaceuticals Inc, H2

Peritoneal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H2

Peritoneal Cancer - Pipeline by Oxford BioMedica Plc, H2

Peritoneal Cancer - Pipeline by Pfizer Inc, H2

Peritoneal Cancer - Pipeline by Pharma Mar SA, H2

Peritoneal Cancer - Pipeline by Polaris Pharmaceuticals Inc, H2

Peritoneal Cancer - Pipeline by PsiOxus Therapeutics Ltd, H2

Peritoneal Cancer - Pipeline by PTC Therapeutics Inc, H2

Peritoneal Cancer - Pipeline by Richter Gedeon Nyrt, H2

Peritoneal Cancer - Pipeline by Rigel Pharmaceuticals Inc, H2

Peritoneal Cancer - Pipeline by Samyang Holdings Corp, H2

Peritoneal Cancer - Pipeline by Sanofi, H2

Peritoneal Cancer - Pipeline by Sanofi Pasteur SA, H2

Peritoneal Cancer - Pipeline by Sotio AS, H2

Peritoneal Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H2

Peritoneal Cancer - Pipeline by Syndax Pharmaceuticals Inc, H2

Peritoneal Cancer - Pipeline by TapImmune Inc, H2

Peritoneal Cancer - Pipeline by Tyrogenex Inc, H2

Peritoneal Cancer - Pipeline by Vascular Biogenics Ltd, H2

Peritoneal Cancer - Pipeline by Verastem Inc, H2

Peritoneal Cancer - Pipeline by Vyriad Inc, H2

Peritoneal Cancer - Dormant Projects, H2

Peritoneal Cancer - Dormant Projects, H2 2017 (Contd..1), H2

Peritoneal Cancer - Dormant Projects, H2 2017 (Contd..2), H2

Peritoneal Cancer - Discontinued Products, H2

List of Figures

Number of Products under Development for Peritoneal Cancer, H2

Number of Products under Development by Companies, H2

Number of Products under Development by Universities/Institutes, H2

Number of Products by Top 10 Targets, H2

Number of Products by Stage and Top 10 Targets, H2

Number of Products by Top 10 Mechanism of Actions, H2

Number of Products by Stage and Top 10 Mechanism of Actions, H2

Number of Products by Top 10 Routes of Administration, H2

Number of Products by Stage and Top 10 Routes of Administration, H2

Number of Products by Top 10 Molecule Types, H2

Number of Products by Stage and Top 10 Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • 3-V Biosciences Inc
  • AbbVie Inc
  • Adaptimmune Therapeutics Plc
  • Aduro BioTech Inc
  • Advenchen Laboratories LLC
  • Altor BioScience Corp
  • Amgen Inc
  • Arrien Pharmaceuticals LLC
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Atara Biotherapeutics Inc
  • AVEO Pharmaceuticals Inc
  • Bayer AG
  • BeiGene Ltd
  • Boehringer Ingelheim GmbH
  • Boston Biomedical Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Celsion Corp
  • CerRx Inc
  • Chipscreen Biosciences Ltd
  • Clovis Oncology Inc
  • Critical Outcome Technologies Inc
  • Dr. Reddy's Laboratories Ltd
  • Eisai Co Ltd
  • Eli Lilly and Co
  • EpiThany Inc
  • Exelixis Inc
  • F. Hoffmann-La Roche Ltd
  • Galena Biopharma Inc
  • Gene Techno Science Co Ltd
  • Genelux Corp
  • Genentech Inc
  • Genor BioPharma Co Ltd
  • Glycotope GmbH
  • Gradalis Inc
  • Hemispherx Biopharma Inc
  • ImmunoGen Inc
  • Immunovaccine Inc
  • Innate Immunotherapeutics Ltd
  • Innate Pharma SA
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Juno Therapeutics Inc
  • Kyowa Hakko Kirin Co Ltd
  • Lidds AB
  • Mabion SA
  • MabVax Therapeutics Holdings Inc
  • Madrigal Pharmaceuticals Inc.
  • MedImmune LLC
  • Medivir AB
  • Merck & Co Inc
  • Merck KGaA
  • Millennium Pharmaceuticals Inc
  • MolMed SpA
  • Mycenax Biotech Inc
  • NewLink Genetics Corp
  • Novartis AG
  • Novogen Ltd
  • Oasmia Pharmaceutical AB
  • OBI Pharma Inc
  • Oncobiologics Inc
  • Oncolix Inc
  • Oncolytics Biotech Inc
  • OncoMed Pharmaceuticals Inc
  • Ono Pharmaceutical Co Ltd
  • Oxford BioMedica Plc
  • Pfizer Inc
  • Pharma Mar SA
  • Polaris Pharmaceuticals Inc
  • PsiOxus Therapeutics Ltd
  • PTC Therapeutics Inc
  • Richter Gedeon Nyrt
  • Rigel Pharmaceuticals Inc
  • Samyang Holdings Corp
  • Sanofi
  • Sanofi Pasteur SA
  • Sotio AS
  • Sun Pharma Advanced Research Company Ltd
  • Syndax Pharmaceuticals Inc
  • TapImmune Inc
  • Tyrogenex Inc
  • Vascular Biogenics Ltd
  • Verastem Inc
  • Vyriad Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll